<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, CA USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26990090</article-id>
      <article-id pub-id-type="pmc">4798776</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0151429</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-15-53331</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Neurology</subject>
            <subj-group>
              <subject>Neurodegenerative Diseases</subject>
              <subj-group>
                <subject>Movement Disorders</subject>
                <subj-group>
                  <subject>Ataxia</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Neurology</subject>
            <subj-group>
              <subject>Neurodegenerative Diseases</subject>
              <subj-group>
                <subject>Movement Disorders</subject>
                <subj-group>
                  <subject>Dystonia</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Diagnostic Medicine</subject>
            <subj-group>
              <subject>Diagnostic Radiology</subject>
              <subj-group>
                <subject>Magnetic Resonance Imaging</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Research and Analysis Methods</subject>
          <subj-group>
            <subject>Imaging Techniques</subject>
            <subj-group>
              <subject>Diagnostic Radiology</subject>
              <subj-group>
                <subject>Magnetic Resonance Imaging</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Radiology and Imaging</subject>
            <subj-group>
              <subject>Diagnostic Radiology</subject>
              <subj-group>
                <subject>Magnetic Resonance Imaging</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Medicine and Health Sciences</subject>
          <subj-group>
            <subject>Pathology and Laboratory Medicine</subject>
            <subj-group>
              <subject>Signs and Symptoms</subject>
              <subj-group>
                <subject>Atrophy</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Molecular Biology</subject>
            <subj-group>
              <subject>Molecular Biology Techniques</subject>
              <subj-group>
                <subject>Sequencing Techniques</subject>
                <subj-group>
                  <subject>Sequence Analysis</subject>
                  <subj-group>
                    <subject>Sequence Motif Analysis</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Research and Analysis Methods</subject>
          <subj-group>
            <subject>Molecular Biology Techniques</subject>
            <subj-group>
              <subject>Sequencing Techniques</subject>
              <subj-group>
                <subject>Sequence Analysis</subject>
                <subj-group>
                  <subject>Sequence Motif Analysis</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Cell Biology</subject>
            <subj-group>
              <subject>Cellular Types</subject>
              <subj-group>
                <subject>Animal Cells</subject>
                <subj-group>
                  <subject>Neurons</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Biology and Life Sciences</subject>
          <subj-group>
            <subject>Cell Biology</subject>
            <subj-group>
              <subject>Cellular Structures and Organelles</subject>
              <subj-group>
                <subject>Cell Membranes</subject>
                <subj-group>
                  <subject>Membrane Proteins</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v3">
          <subject>Physical Sciences</subject>
          <subj-group>
            <subject>Physics</subject>
            <subj-group>
              <subject>Condensed Matter Physics</subject>
              <subj-group>
                <subject>Solid State Physics</subject>
                <subj-group>
                  <subject>Crystallography</subject>
                  <subj-group>
                    <subject>Crystal Structure</subject>
                  </subj-group>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>ATP1A3</italic> Mutation in Adult Rapid-Onset Ataxia</article-title>
        <alt-title alt-title-type="running-head">Genetic Basis of a Rapid-Onset Ataxia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sweadner</surname>
            <given-names>Kathleen J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff001">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor001">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Toro</surname>
            <given-names>Camilo</given-names>
          </name>
          <xref ref-type="aff" rid="aff002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Whitlow</surname>
            <given-names>Christopher T.</given-names>
          </name>
          <xref ref-type="aff" rid="aff003">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Snively</surname>
            <given-names>Beverly M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff004">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cook</surname>
            <given-names>Jared F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff005">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ozelius</surname>
            <given-names>Laurie J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff006">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Markello</surname>
            <given-names>Thomas C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff007">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brashear</surname>
            <given-names>Allison</given-names>
          </name>
          <xref ref-type="aff" rid="aff005">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff001">
        <label>1</label>
        <addr-line>Departments of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America</addr-line>
      </aff>
      <aff id="aff002">
        <label>2</label>
        <addr-line>NIH Undiagnosed Diseases Program, Common Fund, Office of the Director, NIH, and Office of the Clinical Director, NHGRI, Bethesda, Maryland, United States of America</addr-line>
      </aff>
      <aff id="aff003">
        <label>3</label>
        <addr-line>Departments of Radiology and Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
      </aff>
      <aff id="aff004">
        <label>4</label>
        <addr-line>Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
      </aff>
      <aff id="aff005">
        <label>5</label>
        <addr-line>Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
      </aff>
      <aff id="aff006">
        <label>6</label>
        <addr-line>Department of Neurology, Massachusetts General Hospital, Boston Massachusetts, United States of America</addr-line>
      </aff>
      <aff id="aff007">
        <label>7</label>
        <addr-line>NIH Undiagnosed Diseases Program, Common Fund, Office of the Director, NIH, and Human Biochemical Genetics Section, Medical Genetics Branch, NHGRI, Bethesda, Maryland, United States of America</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>LeDoux</surname>
            <given-names>Mark S.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>University of Tennessee Health Science Center, UNITED STATES</addr-line>
      </aff>
      <author-notes>
        <fn fn-type="conflict" id="coi001">
          <p><bold>Competing Interests: </bold>KJS, CT, CTW, BMS, JFC, LJO, and TCM have declared that no competing interests exist. AB is a consultant to Allergan, Ipsen, Concert and Revance. Her conflict of interest was managed by Wake Forest School of Medicine. This did not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
        </fn>
        <fn fn-type="con" id="contrib001">
          <p>Conceived and designed the experiments: KJS CT TCM AB. Performed the experiments: KJS CT CTW JC AB. Analyzed the data: KJS BMS JC TCM AB. Contributed reagents/materials/analysis tools: LO. Wrote the paper: KJS CT BS LO AB.</p>
        </fn>
        <corresp id="cor001">* E-mail: <email>sweadner@helix.mgh.harvard.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>11</volume>
      <issue>3</issue>
      <elocation-id>e0151429</elocation-id>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
          <license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0151429.pdf"/>
      <abstract>
        <p>A 21-year old male presented with ataxia and dysarthria that had appeared over a period of months. Exome sequencing identified a <italic>de novo</italic> missense variant in <italic>ATP1A3</italic>, the gene encoding the &#x3B1;3 subunit of Na,K-ATPase. Several lines of evidence suggest that the variant is causative. <italic>ATP1A3</italic> mutations can cause rapid-onset dystonia-parkinsonism (RDP) with a similar age and speed of onset, as well as severe diseases of infancy. The patient&#x2019;s <italic>ATP1A3</italic> p.Gly316Ser mutation was validated in the laboratory by the impaired ability of the expressed protein to support the growth of cultured cells. In a crystal structure of Na,K-ATPase, the mutated amino acid was directly apposed to a different amino acid mutated in RDP. Clinical evaluation showed that the patient had many characteristics of RDP, however he had minimal fixed dystonia, a defining symptom of RDP. Successive magnetic resonance imaging (MRI) revealed progressive cerebellar atrophy, explaining the ataxia. The absence of dystonia in the presence of other RDP symptoms corroborates other evidence that the cerebellum contributes importantly to dystonia pathophysiology. We discuss the possibility that a second <italic>de novo</italic> variant, in ubiquilin 4 (<italic>UBQLN4</italic>), a ubiquitin pathway component, contributed to the cerebellar neurodegenerative phenotype and differentiated the disease from other manifestations of <italic>ATP1A3</italic> mutations. We also show that a homozygous variant in <italic>GPRIN1</italic> (G protein-regulated inducer of neurite outgrowth 1) deletes a motif with multiple copies and is unlikely to be causative.</p>
      </abstract>
      <funding-group>
        <funding-statement>The Undiagnosed Diseases Program is funded by the Common Fund of the National Institutes of Health. This study was supported by National Institutes of Health (NIH) grant 5R01 NS058949 to AB, and by the National Institutes of Health (NIH) Undiagnosed Diseases Program HSSN30221300096P to AB and HSSN268201300238P to KJS.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="2"/>
        <page-count count="12"/>
      </counts>
      <custom-meta-group>
        <custom-meta id="data-availability">
          <meta-name>Data Availability</meta-name>
          <meta-value>The deposition of exome data generated in the NIH Undiagnosed Diseases Program are pending at dbGaP, and this dataset will be annotated with the gene name ATP1A3 and this publication. All other relevant data are within the paper and its Supporting Information files.</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <title>Data Availability</title>
      <p>The deposition of exome data generated in the NIH Undiagnosed Diseases Program are pending at dbGaP, and this dataset will be annotated with the gene name ATP1A3 and this publication. All other relevant data are within the paper and its Supporting Information files.</p>
    </notes>
  </front>
  <body>
    <sec sec-type="intro" id="sec001">
      <title>Introduction</title>
      <p>A patient with unexpected adult onset of ataxia and rapid deterioration had exome sequencing performed by the NIH Undiagnosed Diseases Program [<xref rid="pone.0151429.ref001" ref-type="bibr">1</xref>], which uncovered candidate gene mutations. A <italic>de novo</italic> mutation was found in <italic>ATP1A3</italic>, which encodes the &#x3B1;3 subunit isoform of the Na,K-ATPase catalytic subunit. Of the three isoforms of the catalytic (&#x3B1;) subunit expressed in the CNS, &#x3B1;3 is found only in neurons [<xref rid="pone.0151429.ref002" ref-type="bibr">2</xref>]. Na,K-ATPase transports Na<sup>+</sup> out of the cell and K<sup>+</sup> into the cell. This isoform is so important to brain function that dominantly-inherited mutations can produce cognitive impairment, developmental delay, psychiatric disorders, seizures, and several specific syndromes that differ in severity, age of onset, and triggers [<xref rid="pone.0151429.ref003" ref-type="bibr">3</xref>&#x2013;<xref rid="pone.0151429.ref007" ref-type="bibr">7</xref>]. Mutations in <italic>ATP1A3</italic> produce rapid-onset dystonia-parkinsonism (RDP) [<xref rid="pone.0151429.ref008" ref-type="bibr">8</xref>]; alternating hemiplegia of childhood (AHC) [<xref rid="pone.0151429.ref009" ref-type="bibr">9</xref>], and severe infantile epilepsy [<xref rid="pone.0151429.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0151429.ref011" ref-type="bibr">11</xref>]. Ataxia has appeared with <italic>ATP1A3</italic> mutations in a syndrome with cerebellar ataxia, areflexia, pes cavus, optic nerve atrophy, and sensorimotor deafness (CAPOS) [<xref rid="pone.0151429.ref012" ref-type="bibr">12</xref>], and in pediatric cases where febrile episodes resulted in relapsing ataxia combined variably with symptoms shared with RDP and/or AHC [<xref rid="pone.0151429.ref013" ref-type="bibr">13</xref>&#x2013;<xref rid="pone.0151429.ref016" ref-type="bibr">16</xref>], including one patient with an ataxia episode as an adult [<xref rid="pone.0151429.ref015" ref-type="bibr">15</xref>]. In RDP, disease onset often follows a stressful trigger and usually develops over a period of hours to weeks or months. Neuropathology has been described in aged RDP patients [<xref rid="pone.0151429.ref017" ref-type="bibr">17</xref>], however none of the <italic>ATP1A3</italic>-related diseases have been considered neurodegenerative. We expressed the patient&#x2019;s novel <italic>de novo ATP1A3</italic> mutation and tested its function to investigate its potential pathogenicity.</p>
      <p>A second <italic>de novo</italic> variant was in <italic>UBQLN4</italic>, which encodes ubiquilin 4, an adaptor protein involved in ubiquitin-directed protein quality control. The <italic>UBQLN4</italic> homologs <italic>UBQLN1</italic> and <italic>UBQLN2</italic> have been implicated in the pathogenesis of neurodegenerative diseases, i.e. Parkinson&#x2019;s, Alzheimer&#x2019;s, Huntington's, and amyotrophic lateral sclerosis/frontotemporal dementia [<xref rid="pone.0151429.ref018" ref-type="bibr">18</xref>]. The patient&#x2019;s <italic>UBQLN4</italic> variant was compared to previously-identified causative mutations in its homologs, and similarity supports the idea that it may have contributed to the atypical ataxia of this individual as part of a response to misfolded protein. An inherited deletion in <italic>GPRIN1</italic>, however, showed genetic and sequence characteristics of a tolerated variant.</p>
    </sec>
    <sec id="sec002">
      <title>Subjects and Methods</title>
      <sec id="sec003">
        <title>Clinical evaluation</title>
        <p>The patient had clinical evaluations initially at NIH and later at Wake Forest School of Medicine, where a battery of tests developed for RDP patients ([<xref rid="pone.0151429.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0151429.ref015" ref-type="bibr">15</xref>] and <xref ref-type="supplementary-material" rid="pone.0151429.s001">S1 File</xref>) was administered. At the NIH, the patient and his nuclear family were evaluated under the auspices of the NIH Undiagnosed Diseases Program (UDP) and all were enrolled under NIH protocol 76-HG-0238, &#x201C;Diagnosis and Treatment of Patients with Inborn Errors of Metabolism and Other Genetic Disorders&#x201D;, a study approved and monitored by the Intramural NHGRI Ethics Review Board. At Wake Forest, the study was approved by the Wake Forest School of Medicine Institutional Review Board. All participants were adult and capable of informed consent, and written informed consent was obtained.</p>
      </sec>
      <sec id="sec004">
        <title>Genetic studies</title>
        <p>High-density SNP mapping and exome sequencing were performed on the patient, his parents (of Swiss origin), and sibling. Variants were filtered by a multi-step pipeline developed by the Undiagnosed Diseases Program that utilizes haplotype mapping and pedigree structure, and filters variants by multiple technical criteria and different inheritance models [<xref rid="pone.0151429.ref019" ref-type="bibr">19</xref>]. Variants of interest were validated by Sanger sequencing.</p>
      </sec>
      <sec id="sec005">
        <title>Mutation structure and function</title>
        <p>Na,K-ATPase &#x3B1;1 and &#x3B1;3 are 88% identical. Homologous residues were identified in the crystal structures of <italic>ATP1A1</italic> Na,K-ATPase in the K<sup>+</sup>-bound and Na<sup>+</sup>-bound conformations (PDB ID&#x2019;s 2ZXE and 3WGU) [<xref rid="pone.0151429.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0151429.ref021" ref-type="bibr">21</xref>] and analyzed with the Swiss PDV Viewer, SPDBV 4.1. The p.Gly316Ser mutation was introduced into human <italic>ATP1A3</italic> cDNA in an expression vector previously mutated to be resistant to the inhibitor ouabain [<xref rid="pone.0151429.ref008" ref-type="bibr">8</xref>]. It was expressed transiently in HEK293 cells, which have endogenous ouabain-sensitive <italic>ATP1A1</italic>. An established cell survival assay was employed to determine whether the introduced <italic>ATP1A3</italic> Na,K-ATPase is active enough to functionally replace the endogenous <italic>ATP1A1</italic> Na,K-ATPase when it is inhibited [<xref rid="pone.0151429.ref008" ref-type="bibr">8</xref>]. Gel electrophoresis and staining with ATP1A3-specific antibodies were performed as described [<xref rid="pone.0151429.ref010" ref-type="bibr">10</xref>].</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec006">
      <title>Results</title>
      <sec id="sec007">
        <title>Phenotype</title>
        <p>The patient had normal gestation, delivery and early development except for mild amblyopia. His gross and fine motor developmental milestones were achieved on target, but speech was delayed until 2 years of age. He exhibited a mild learning disability and dyslexia, but no developmental regression. At age 19 he had unexplained episodes of vertigo lasting days, which resolved. Difficulties with balance and gait, slurred speech and drooling emerged at age 21 and worsened during a summer spent away from home. A tremor of the hands (primarily action tremor) was subsequently noticed as well. These symptoms progressed over the next 6 months with profound dysarthria and ataxia that led to the use of a wheelchair. The patient&#x2019;s mother reported that the symptoms progressed most rapidly over the last 2 months of this period and then stabilized.</p>
        <p>When evaluated at the NIH at age 24, the patient had findings of a moderate to severe cerebellar syndrome with limb and gait ataxia and cerebellar dysarthria. His movements were slow, speech was soft, and he ambulated with small steps. He had mildly elevated tone worse in the lower extremities. Longitudinal MRI imaging demonstrated progressive cerebellar degeneration (<xref ref-type="fig" rid="pone.0151429.g001">Fig 1A</xref>). No peripheral nervous system involvement was found by exam or electrodiagnostic studies; spinal fluid neurotransmitters and muscle biopsies were normal; and there was no benefit from a trial of levodopa: 25 mg carbidopa/100 mg levodopa 3 times a day for ~ 2 months in 2011. Testing for the following disorders were negative: encephalitis, immune disease, metabolic or mitochondrial disease, lysosomal storage diseases, and spinocerebellar ataxias.</p>
        <fig id="pone.0151429.g001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0151429.g001</object-id>
          <label>Fig 1</label>
          <caption>
            <title>Sequential and comparative MRI.</title>
            <p>(A) Axial T1-weighted images from successive MRI scans acquired from 2008 (year of onset) to 2014 demonstrate the progressive development of cerebellar atrophy. (B) Coronal (top row) and sagittal (bottom row) T1-weighted images from MRI demonstrate relatively normal cerebellar structure and volume of a representative RDP patient (left images) in contrast to marked cerebellar atrophy of the patient in 2014 (right images).</p>
          </caption>
          <graphic xlink:href="pone.0151429.g001"/>
        </fig>
        <p>The patient has taken a vitamin compound for the past 3 years, which the family reported benefitted speech, gait, balance, and tremor. The total daily dose is B1, 100 mg; B2, 200 mg; B5, 200 mg; C, 500 mg; E, 400 IU; folinic acid 10 mg; selenium 50 &#x3BC;g; coenzyme Q-10 500 mg; lipoic acid 500 mg; and biotin 10 mg.</p>
        <p>Before identification of the gene, RDP had not been considered in the diagnosis because of the patient&#x2019;s profound ataxia. <italic>ATP1A3</italic> mutation and rapid development of severe symptoms made an association more likely. Follow-up evaluation of the patient at age 26 at Wake Forest School of Medicine revealed partial overlap of clinical features with RDP. Video is in the <xref ref-type="supplementary-material" rid="pone.0151429.s002">S1 Video</xref>. A patient history questionnaire and neurological exam that were developed for RDP patients was administered. No substance use or chemical exposure was reported that might have triggered or caused the symptoms. The principal similarities to RDP were dysarthria, including difficulty with speech, swallowing, and drooling (common manifestations in RDP) [<xref rid="pone.0151429.ref003" ref-type="bibr">3</xref>], prominent bradykinesia and masked face, a history of childhood learning difficulties, and relatively rapid onset of symptoms as a young adult. The most notable differences from RDP were that ataxia predominated instead of dystonia, and there was tremor of the hands. Neuropathology and MRI of RDP patients shows detectable pathology in dentate nucleus and superior cerebellar peduncle, but not extensive atrophy [<xref rid="pone.0151429.ref017" ref-type="bibr">17</xref>]. In contrast, the patient at age 26 showed severe cerebellar atrophy, contrasting with an image from an age- and sex-matched RDP patient (<xref ref-type="fig" rid="pone.0151429.g001">Fig 1B</xref>). Motor test scores are listed in <xref ref-type="table" rid="pone.0151429.t001">Table 1</xref> compared to the mean scores of RDP patients in our database. A high score for RDP severity was based on findings of definite affected arm and bulbar muscles and that the patient uses a wheelchair.</p>
        <table-wrap id="pone.0151429.t001" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0151429.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Neurological evaluation.</title>
          </caption>
          <alternatives>
            <graphic id="pone.0151429.t001g" xlink:href="pone.0151429.t001"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="center" rowspan="1" colspan="1">Test</th>
                  <th align="center" rowspan="1" colspan="1">Score</th>
                  <th align="center" rowspan="1" colspan="1">RDP average</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>UPDRS-III, motor subscore</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">30</td>
                  <td align="center" rowspan="1" colspan="1">31.9</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>BFMS dystonia rating</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">3</td>
                  <td align="center" rowspan="1" colspan="1">55.7</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>IADL activities of daily living</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1">15</td>
                  <td align="center" rowspan="1" colspan="1">22.0</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>RDP neurologic examination:</bold>
                  </td>
                  <td align="center" rowspan="1" colspan="1"/>
                  <td align="center" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;&#xA0;<bold>dystonia</bold></td>
                  <td align="center" rowspan="1" colspan="1">2</td>
                  <td align="center" rowspan="1" colspan="1">3.97</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;&#xA0;<bold>parkinsonism</bold></td>
                  <td align="center" rowspan="1" colspan="1">3</td>
                  <td align="center" rowspan="1" colspan="1">3.72</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">&#xA0;&#xA0;&#xA0;&#xA0;<bold>RDP severity</bold></td>
                  <td align="center" rowspan="1" colspan="1">4</td>
                  <td align="center" rowspan="1" colspan="1">3.22</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t001fn001">
              <p>The tests administered were:</p>
            </fn>
            <fn id="t001fn002">
              <p>Unified Parkinson&#x2019;s Disease Rating Scale (UPDRS)[<xref rid="pone.0151429.ref022" ref-type="bibr">22</xref>]; Burke-Fahn-Marsden Dystonia Rating Scale (BFMS)[<xref rid="pone.0151429.ref023" ref-type="bibr">23</xref>]; Instrumental Activities of Daily Living (IADL)[<xref rid="pone.0151429.ref024" ref-type="bibr">24</xref>]; RDP Neurologic Examination: dystonia and parkinsonism scores = 1, no dystonia/parkinsonism, 2, possible, 3, probable, and 4, definite. RDP severity = 1, limb dystonia only including writer&#x2019;s cramp, 2, affected arm and bulbar muscles with normal gait, 3, same as 2 with legs affected but walking unassisted, and 4, same as 2 with legs affected but walking with walker or in a wheelchair.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Previously, findings of cognitive impairment and psychosis in RDP led to development of a comprehensive battery of cognitive and psychiatric tests suitable for people with motor limitations [<xref rid="pone.0151429.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0151429.ref026" ref-type="bibr">26</xref>], which were administered to this patient. In the psychiatric battery (CIDI DSM-IV and ICD-10; HAM-A and&#x2013;D; Y-BOCS) the patient was within normal limits, while taking clonazepam 0.5 mg daily for anxiety. A comprehensive battery of neuropsychological tests showed overall skills at the low end of average, verbal and nonverbal skills evenly matched, and memory within normal limits (verbal &gt; nonverbal). However there was poor discrimination on delayed recognition of abstract designs, and impaired psychomotor processing speed, with performance limited by motor impairment. The data for psychiatric and cognitive testing are Tables A and B in <xref ref-type="supplementary-material" rid="pone.0151429.s001">S1 File</xref>.</p>
      </sec>
      <sec id="sec008">
        <title>Genetics</title>
        <p>Analysis of exome sequences of the patient and his family identified four candidate variants (<xref ref-type="table" rid="pone.0151429.t002">Table 2</xref>). Two candidates, <italic>ATP1A3</italic> and <italic>UBQLN4</italic>, were heterozygous and de novo, and two others were inherited. The potential of <italic>UBQLN4</italic> and <italic>GPRIN1</italic> as candidates is discussed below. X-linked <italic>SRPK3</italic> is a member of a family of kinases that regulate RNA processing. However, in humans, mice, and pigs it is implicated in myogenesis and highly expressed in muscle but not brain [<xref rid="pone.0151429.ref027" ref-type="bibr">27</xref>]. Other variants that did not score as possibly causative included four additional homozygous variants inherited from the parents (<italic>RFX5</italic>, <italic>FAM194</italic>, <italic>OR1L6</italic>, <italic>COMMD10</italic>)<italic>;</italic> two additional hemizygous X-linked variants (<italic>SSX3</italic>, <italic>USP11</italic>); four compound heterozygous variants (<italic>CYP2C18</italic>, <italic>KL</italic>, <italic>TTN</italic>, <italic>PLEC</italic>)<italic>;</italic> and one inherited heterozygous variants (<italic>KARS</italic>).</p>
        <table-wrap id="pone.0151429.t002" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0151429.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Candidate variants detected by exome sequencing.</title>
          </caption>
          <alternatives>
            <graphic id="pone.0151429.t002g" xlink:href="pone.0151429.t002"/>
            <table frame="hsides" rules="groups">
              <colgroup span="1">
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
                <col align="left" valign="middle" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" rowspan="1" colspan="1"/>
                  <th align="left" rowspan="1" colspan="1">Chr</th>
                  <th align="left" rowspan="1" colspan="1">RefSeq</th>
                  <th align="left" rowspan="1" colspan="1">variant</th>
                  <th align="left" rowspan="1" colspan="1">patient</th>
                  <th align="left" rowspan="1" colspan="1">mother</th>
                  <th align="left" rowspan="1" colspan="1">father</th>
                  <th align="left" rowspan="1" colspan="1">brother</th>
                  <th align="left" rowspan="1" colspan="1">ref</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>
                      <italic>ATP1A3</italic>
                    </bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">19</td>
                  <td align="left" rowspan="1" colspan="1">NM_152296.3</td>
                  <td align="left" rowspan="1" colspan="1">[c.946G&gt;A, p.Gly316Ser]</td>
                  <td align="left" rowspan="1" colspan="1">A/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>
                      <italic>UBQLN4</italic>
                    </bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">NM_020131.3</td>
                  <td align="left" rowspan="1" colspan="1">[c.1444G&gt;A, p.Glu482Lys]</td>
                  <td align="left" rowspan="1" colspan="1">A/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                  <td align="left" rowspan="1" colspan="1">G/G</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>
                      <italic>GPRIN1</italic>
                    </bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">5</td>
                  <td align="left" rowspan="1" colspan="1">NM_052899.2</td>
                  <td align="left" rowspan="1" colspan="1">[c.690_714delinsA, p.Glu233_Lys240insA] + [c.690_714delinsA, p.Glu233_Lys240insA]</td>
                  <td align="left" rowspan="1" colspan="1">homo-del</td>
                  <td align="left" rowspan="1" colspan="1">het-del</td>
                  <td align="left" rowspan="1" colspan="1">het-del</td>
                  <td align="left" rowspan="1" colspan="1">homo-ref</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>
                      <italic>SRPK3</italic>
                    </bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1">X</td>
                  <td align="left" rowspan="1" colspan="1">NM_014370.2</td>
                  <td align="left" rowspan="1" colspan="1">[c.1373C&gt;A, p.Thr458Asn]</td>
                  <td align="left" rowspan="1" colspan="1">hemiA</td>
                  <td align="left" rowspan="1" colspan="1">A/C</td>
                  <td align="left" rowspan="1" colspan="1">hemi C</td>
                  <td align="left" rowspan="1" colspan="1">hemi C</td>
                  <td align="left" rowspan="1" colspan="1">C/C</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">
                    <bold>status</bold>
                  </td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">affected</td>
                  <td align="left" rowspan="1" colspan="1">unaffected</td>
                  <td align="left" rowspan="1" colspan="1">unaffected</td>
                  <td align="left" rowspan="1" colspan="1">unaffected</td>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="t002fn001">
              <p>Ref is the reference sequence, del is deletion. <italic>ATP1A3</italic> = &#x3B1;3 catalytic subunit of Na,K-ATPase; <italic>UBQLN4</italic> = ubiquilin-4. <italic>GPRIN1</italic> = G-protein-regulated inducer of neurite outgrowth 1; SRPK3 = serine arginine domain selective protein kinase 3. All variants were verified by Sanger sequencing.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Mutations in <italic>ATP1A3</italic> produce neurologic disease [<xref rid="pone.0151429.ref028" ref-type="bibr">28</xref>]. The protein has 10 transmembrane spans, and cycles through conformation changes that alternately bind Na<sup>+</sup> or K<sup>+</sup> in binding pockets in the middle of the membrane. p.Gly316Ser mutation is novel, and is in the highly conserved 4th transmembrane span. In a Na,K-ATPase crystal structure in the K<sup>+</sup>-bound conformation, p.Gly316Ser is directly apposed to a residue in the 5<sup>th</sup> transmembrane span that is mutated in RDP (p.Phe780Leu) (<xref ref-type="fig" rid="pone.0151429.g002">Fig 2</xref>, top) [<xref rid="pone.0151429.ref008" ref-type="bibr">8</xref>]. The glycine is &lt;3.7&#xC5; from the side chain of the phenylalanine, whereas the side chain of serine is polar and would clash with the phenylalanine at &lt;2.2&#xC5;. The mutations are close to the ion binding pocket. In the Na<sup>+</sup>-bound conformation, in contrast, the glycine and phenylalanine are 11 &#xC5; apart because of a sliding rearrangement of the transmembrane spans (<xref ref-type="fig" rid="pone.0151429.g002">Fig 2</xref>, bottom). Contact of the mutated glycine and phenylalanine residues is thus involved in conformation change during ion pump activity, and is a credible basis for impairment of activity.</p>
        <fig id="pone.0151429.g002" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0151429.g002</object-id>
          <label>Fig 2</label>
          <caption>
            <title>Stereo images of Gly316 and Phe780 in the K<sup>+</sup> and Na<sup>+</sup> conformations.</title>
            <p>The structures can be viewed in stereo by focusing the eyes behind the plane of the top or bottom image pair and letting the eyes drift separately until a central image fuses. On the top, the transmembrane domain of Na,K-ATPase is shown from a crystal structure in the E2 (K<sup>+</sup>-bound) conformation. Gold spheres are K<sup>+</sup> ions in the ion binding pocket. The yellow space-fill residue is Gly316. Opposite it, the blue-green residue is Phe780, mutated to leucine in RDP. On the bottom, red spheres are Na<sup>+</sup> ions in the ion binding pocket of a crystal structure in the E1 (Na<sup>+</sup> bound) conformation. The rearrangement of transmembrane helices has separated Gly316 and Phe780 significantly.</p>
          </caption>
          <graphic xlink:href="pone.0151429.g002"/>
        </fig>
      </sec>
      <sec id="sec009">
        <title>ATP1A3 mutation validation and phenotype</title>
        <p>Cellular expression studies were performed to test whether the p.Gly316Ser <italic>ATP1A3</italic> mutation impairs the activity of the enzyme. The test is a survival assay, in which only active enzyme can keep the cells viable when their endogenous Na,K-ATPase is inhibited. The mutation was introduced into a ouabain-resistant cDNA of human <italic>ATP1A3</italic> and expressed in a ouabain-sensitive human cell line, HEK 293. Addition of ouabain killed control cells that expressed no <italic>ATP1A3</italic> (<xref ref-type="fig" rid="pone.0151429.g003">Fig 3A</xref>). Expression of wild-type, ouabain-resistant <italic>ATP1A3</italic> allowed cells to survive and divide normally (<xref ref-type="fig" rid="pone.0151429.g003">Fig 3B</xref>). The cultures double every 24 hours, and evidence of cell crowding (asterisks) and dying cells (black arrows) was seen. Within a few more days, cultures with WT <italic>ATP1A3</italic> (like untransfected cultures) were too crowded to be viable (not shown). Cells expressing the p.Gly316Ser mutation survived for 2&#x2013;3 weeks in stasis but could not divide, remained uncrowded, and were gradually lost (<xref ref-type="fig" rid="pone.0151429.g003">Fig 3C</xref>). At the edges of open spaces on the plate, cells with WT <italic>ATP1A3</italic> were well-flattened (white arrowheads), while those with pGly316Ser were more rounded. Other p.Gly316Ser-transfected wells were trypsinized at 96 h and replated in 0.5 &#x3BC;M ouabain, and these had no surviving cells after 3 d (not shown). Na,K-ATPase &#x3B1;3 expression levels assessed by Western blot were close to those of the WT controls (<xref ref-type="fig" rid="pone.0151429.g003">Fig 3D</xref>). The data indicate that there is impaired pump activity, with just enough residual activity to maintain cell stasis, but not viability. Partial inhibition of activity, often with reduced Na<sup>+</sup> affinity, has been reported for RDP mutations [<xref rid="pone.0151429.ref028" ref-type="bibr">28</xref>]. In contrast, mutations producing severe disease in infants (AHC or severe epilepsy) did not support cell survival at all in the same assay [<xref rid="pone.0151429.ref010" ref-type="bibr">10</xref>]</p>
        <fig id="pone.0151429.g003" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0151429.g003</object-id>
          <label>Fig 3</label>
          <caption>
            <title>Impairment of Na,K-ATPase function.</title>
            <p>(A-C) Ouabain is a specific Na,K-ATPase inhibitor. HEK293 cells are shown 5 d after they were transfected and 4 d after 0.5 &#x3BC;M ouabain was added. In A, mock-transfected HEK cells had all died. In B, transfection was with unmutated <italic>ATP1A3</italic>. Cells survived and divided, becoming crowded (asterisks), medium acidified overnight, and some death due to overcrowding was apparent (arrows). Cells at the edge of open spaces were flattened (white arrowheads). In C, the p.Gly316Ser mutation was transfected. Many cells survived, but were unable to divide, and the medium did not acidify. Over the subsequent two weeks there was a slow attrition of cells and no detectable division of the remaining living p.Gly316Ser cells. (D) Na,K-ATPase &#x3B1;3 western blot of equal amounts of total protein from cell homogenates demonstrating that the mutant protein is expressed at levels comparable to controls. A stable WT <italic>ATP1A3</italic>-transfected cell line was a positive control for optimal <italic>ATP1A3</italic> expression. The visible molecular weight marker (Amersham Rainbow) was 102 kDa, and &#x3B1;3 migrates at ~93 kDa (faster than its molecular mass). HEK cells express only <italic>ATP1A1</italic>, which is not detected by the specific antibody (Santa Cruz Biotechnology sc-16052). The other lanes show transient expression of WT <italic>ATP1A3</italic>, p.Gly316Ser, and p.Glu815Lys, an inactive mutation found in AHC [<xref rid="pone.0151429.ref028" ref-type="bibr">28</xref>]. The expression results and the failure to support cell growth are representative of three experiments.</p>
          </caption>
          <graphic xlink:href="pone.0151429.g003"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="sec010">
      <title>Discussion</title>
      <sec id="sec011">
        <title>Mutation in <italic>ATP1A3</italic></title>
        <p>This is a new phenotype associated with a novel <italic>ATP1A3</italic> mutation. The overlap with RDP in rapid onset and dysarthria and bradykinesia symptoms, the loss of Na,K-ATPase activity, and the conformationally-sensitive proximity of the mutated amino acid to a known RDP mutation (<xref ref-type="fig" rid="pone.0151429.g002">Fig 2</xref>) support a shared etiology. Here ataxia was adult rapid-onset, irreversible, and the predominant symptom. Ataxia frequently manifests in older children with AHC along with a variety of other symptoms [<xref rid="pone.0151429.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0151429.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0151429.ref029" ref-type="bibr">29</xref>], and it appears with other symptoms in children that first manifest symptoms after the 18 month infantile diagnostic cutoff for AHC [<xref rid="pone.0151429.ref013" ref-type="bibr">13</xref>]. A recent case with <italic>ATP1A3</italic> mutation presented with a remitting-relapsing course of acute ataxia triggered by fever [<xref rid="pone.0151429.ref015" ref-type="bibr">15</xref>]. Patients with CAPOS syndrome also exhibit ataxia, and it appears acutely during an illness with fever, and also has a remitting-relapsing course [<xref rid="pone.0151429.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0151429.ref030" ref-type="bibr">30</xref>]. Importantly, hemispheric and vermian cerebellar atrophy is severe in our patient, but in CAPOS and most other <italic>ATP1A3</italic> cases, cranial MRIs are usually normal [<xref rid="pone.0151429.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0151429.ref031" ref-type="bibr">31</xref>], with rare reports of vermian atrophy [<xref rid="pone.0151429.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0151429.ref032" ref-type="bibr">32</xref>].</p>
        <p>Although the neurodegenerative course here is novel, this is the third clinical case linking mutation of <italic>ATP1A3</italic> to neuron death. The neuropathological study of four brains from aged RDP siblings with the p.Ile758Ser mutation demonstrated neuron losses in dentate nucleus, globus pallidus, and other regions implicated in dystonia, with modest losses in cerebellar cortex [<xref rid="pone.0151429.ref017" ref-type="bibr">17</xref>]. In an infant with catastrophic epilepsy and p.Gly358Val <italic>ATP1A3</italic> mutation that severely inhibited the ATPase, cerebellar atrophy was among the neuropathological findings [<xref rid="pone.0151429.ref010" ref-type="bibr">10</xref>]. Whether cell death is causative of symptom onset in <italic>ATP1A3</italic> diseases or an occasional consequence of sustained neurophysiological abnormality is yet to be determined. Here cerebellar atrophy paralleled clinical progression.</p>
        <p>In <italic>ATP1A3</italic> mutations that have been investigated for function, in vitro kinetics and oocyte studies have found only loss of function or reductions in kinetic parameters [<xref rid="pone.0151429.ref028" ref-type="bibr">28</xref>]. A gain of function such as development of a leak current [<xref rid="pone.0151429.ref033" ref-type="bibr">33</xref>] is possible but has not yet been demonstrated for <italic>ATP1A3</italic>, although somatic mutations in <italic>ATP1A1</italic> found in aldosterone-secreting adenomas induced significant leak currents [<xref rid="pone.0151429.ref034" ref-type="bibr">34</xref>]. Three mutations that cause severe AHC have been found to have loss of function and dominant negative effects when coexpressed with normal <italic>ATP1A3</italic> in oocytes [<xref rid="pone.0151429.ref035" ref-type="bibr">35</xref>]. Based on the critical role of the Na,K-ATPase, our patient&#x2019;s p.Gly316Ser <italic>ATP1A3</italic> mutation may be sufficient to cause his disorder.</p>
      </sec>
      <sec id="sec012">
        <title>A potential role for <italic>UBQLN4</italic></title>
        <p><italic>UBQLN4</italic> encodes an adaptor protein linking ubiquitinated proteins and the proteasome. It is not yet associated with human disease, however the <italic>de novo</italic> variant of ubiquilin-4 might have a role in the cerebellar atrophy of this patient. Ubiquitination is involved in two pathways for the degradation of mutated membrane proteins. During biosynthesis in endoplasmic reticulum, the unfolded protein response transports misfolded protein to the cytoplasm where its ubiquitination leads to the proteasome [<xref rid="pone.0151429.ref036" ref-type="bibr">36</xref>], and if a protein is trafficked properly but unstable or misfolded, its ubiquitination leads to autophagy and the lysosome [<xref rid="pone.0151429.ref037" ref-type="bibr">37</xref>]. The role of ubiquilin-4 is not well-studied, but it was discovered as a result of its binding to ataxin-1, whose poly-glutamine expansion causes spinocerebellar atrophy type1 [<xref rid="pone.0151429.ref038" ref-type="bibr">38</xref>]. Ubiquilin-4 is reported to recruit ubiquilin-1 to the proteasome [<xref rid="pone.0151429.ref039" ref-type="bibr">39</xref>]. The homolog <italic>UBQLN2</italic> (ubiquilin-2) on the X chromosome has several gender-independent dominant mutations in a collagen-like proline-X-X repeat that cause ALS-FTD (amyotrophic lateral sclerosis-frontotemporal dementia) [<xref rid="pone.0151429.ref040" ref-type="bibr">40</xref>]. Just upstream of the proline mutations, in a sequence conserved in ubiquilins, is a homozygous <italic>UBQLN2</italic> missense variant, p.Thr467Ile, found in a female FTD patient [<xref rid="pone.0151429.ref041" ref-type="bibr">41</xref>]. Interestingly, the ubiquilin-2 sequence 461-GLQTLA<underline><bold>T</bold></underline>EAPGLIPS-475 aligns with ubiquilin-4 475-GLQTLQT<underline><bold>E</bold></underline>APGLVPS-489, and therefore the UDP patient&#x2019;s heterozygous variant and the FTD-associated homozygous variant are adjacent in the aligned sequence. The functional consequences of the <italic>UBQLN4</italic> p.Glu482Lys variant are not known, but substitutions of negatively charged glutamate with positively charged lysine would be expected to be more disruptive than a threonine to isoleucine change, and the sequence is highly conserved. If the aligned mutations both impair their respective proteins, it would be credible for the <italic>UBQLN4</italic> mutation to reduce the capacity of neurons to dispose of ubiquitinated, misfolded Na,K-ATPase, provided that the <italic>ATP1A3</italic> and <italic>UBQLN4</italic> genes are expressed in the same neurons. In the Allen Brain Atlas [<xref rid="pone.0151429.ref042" ref-type="bibr">42</xref>], the mouse cerebellum shows similar cellular RNA distributions of the two gene products: molecular layer neurons and scattered granular layer neurons, Purkinje cells, and neurons of the dentate nucleus, but not cerebellar granule cells. Mouse Purkinje cell expression of <italic>Atp1a3</italic> is particularly high, a condition that could promote accumulation of misfolded mutated Na,K-ATPase and lead to cell death if the <italic>UBQLN4</italic> variant impaired degradation.</p>
      </sec>
      <sec id="sec013">
        <title>Redundancy in <italic>GPRIN1</italic></title>
        <p>In the patient one identical allele of <italic>GPRIN1</italic> (G-protein-regulated inducer of neurite outgrowth 1) was inherited from each heterozygous parent. In variant databases, the in-frame deletion is a known variant (rs371149640) in a cluster of similar short deletions and SNPs with no associated pathogenesis. The deletion disrupts a motif that is present in multiple copies (<xref ref-type="fig" rid="pone.0151429.g004">Fig 4</xref>). The redundancy of the deleted motif is expected to reduce the likelihood that the deletion is causative of disease. The repeated motifs and other features of the <italic>GPRIN1</italic> protein sequence suggest a scaffolding function consistent with the protein&#x2019;s role in neurite outgrowth and the association of receptors with membrane [<xref rid="pone.0151429.ref043" ref-type="bibr">43</xref>&#x2013;<xref rid="pone.0151429.ref045" ref-type="bibr">45</xref>]. Detail is provided in Figure A in <xref ref-type="supplementary-material" rid="pone.0151429.s001">S1 File</xref>.</p>
        <fig id="pone.0151429.g004" orientation="portrait" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0151429.g004</object-id>
          <label>Fig 4</label>
          <caption>
            <title>Repeated motifs in GPRIN1.</title>
            <p>GPRIN1 (formerly known as GRIN1 until the name conflicted with the official gene name of an NMDA glutamate receptor) has sequence characteristics of a relatively unstructured protein, and in human it has 23 copies, of differing fidelity, of a six amino acid motif typified by KEDPGS. The diagram shows the distribution of motifs (red bars) and the location of an abrupt change of the degree of conservation between human and mouse. The less-conserved segment is likely to be relatively unstructured, and the conserved segment is likely to be compactly folded. One motif copy (green bar) is homozygously deleted in the patient.</p>
          </caption>
          <graphic xlink:href="pone.0151429.g004"/>
        </fig>
      </sec>
      <sec id="sec014">
        <title>Implications for dystonia circuitry</title>
        <p>Adult RDP patients generally manifest fixed dystonia [<xref rid="pone.0151429.ref003" ref-type="bibr">3</xref>], and it would be expected to accompany the other RDP symptoms in this patient. Persistent or recurring dystonia generally develops in AHC patients as well. There is much evidence that dystonia circuits include the cerebellum [<xref rid="pone.0151429.ref046" ref-type="bibr">46</xref>]. Purkinje cell ablation and cerebellectomy block dystonic symptoms in animal models; cerebello-thalamo-cortical tracts are altered in diffusion tensor imaging in patients; in RDP the dentate nucleus showed extensive neuropathology; and Na,K-ATPase inhibition causes abnormal burst firing of Purkinje neurons [<xref rid="pone.0151429.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0151429.ref047" ref-type="bibr">47</xref>&#x2013;<xref rid="pone.0151429.ref050" ref-type="bibr">50</xref>]. The near-absence of dystonia in the presence of severe cerebellar atrophy aligns with the importance of cerebellar output to dystonia pathophysiology.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="sec015">
      <title>Supporting Information</title>
      <supplementary-material content-type="local-data" id="pone.0151429.s001">
        <label>S1 File</label>
        <caption>
          <title>Supplementary data.</title>
          <p>Table A. Psychiatric evaluation. Table B. Neuropsychological evaluation. Figure A. Redundancy of the deleted motif in <italic>GPRIN1</italic>.</p>
          <p>(PDF)</p>
        </caption>
        <media xlink:href="pone.0151429.s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="pone.0151429.s002">
        <label>S1 Video</label>
        <caption>
          <title>Neurological exam of the patient.</title>
          <p>(MP4)</p>
        </caption>
        <media xlink:href="pone.0151429.s002.mp4">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Yi Bessie Liu, John T. Penniston, and Cornelius F. Boerkoel for their help.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0151429.ref001">
        <label>1</label>
        <mixed-citation publication-type="journal"><name><surname>Gahl</surname><given-names>WA</given-names></name>, <name><surname>Markello</surname><given-names>TC</given-names></name>, <name><surname>Toro</surname><given-names>C</given-names></name>, <name><surname>Fuentes Fajardo</surname><given-names>K</given-names></name>, <name><surname>Sincan</surname><given-names>M</given-names></name>, <name><surname>Gill</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases</article-title>. <source>Genet Med</source>. <year>2012</year>;<volume>14</volume>: <fpage>51</fpage>&#x2013;<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/gim.0b013e318232a005">10.1038/gim.0b013e318232a005</ext-link></comment>
<pub-id pub-id-type="pmid">22237431</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref002">
        <label>2</label>
        <mixed-citation publication-type="journal"><name><surname>McGrail</surname><given-names>KM</given-names></name>, <name><surname>Phillips</surname><given-names>JM</given-names></name>, <name><surname>Sweadner</surname><given-names>KJ</given-names></name>. <article-title>Immunofluorescent localization of three Na,K-ATPase isozymes in the rat central nervous system: both neurons and glia can express more than one Na,K-ATPase</article-title>. <source>J Neurosci</source>. <year>1991</year>;<volume>11</volume>: <fpage>381</fpage>&#x2013;<lpage>391</lpage>. <pub-id pub-id-type="pmid">1846906</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref003">
        <label>3</label>
        <mixed-citation publication-type="book"><name><surname>Brashear</surname><given-names>A</given-names></name>, <name><surname>Sweadner</surname><given-names>KJ</given-names></name>, <name><surname>Cook</surname><given-names>JF</given-names></name>, <name><surname>Swoboda</surname><given-names>KJ</given-names></name>, <name><surname>Ozelius</surname><given-names>LJ</given-names></name> (<year>2014</year>) <chapter-title><italic>ATP1A3</italic>-related neurologic disorders</chapter-title> In: <name><surname>Pagon</surname><given-names>RA</given-names></name>, <name><surname>Adam</surname><given-names>MP</given-names></name>, <name><surname>Ardinger</surname><given-names>HH</given-names></name>, <etal>et al</etal>, editors. <source>GeneReviews</source>. <publisher-name>NCBI Bookshelf</publisher-name>.</mixed-citation>
      </ref>
      <ref id="pone.0151429.ref004">
        <label>4</label>
        <mixed-citation publication-type="journal"><name><surname>Rosewich</surname><given-names>H</given-names></name>, <name><surname>Ohlenbusch</surname><given-names>A</given-names></name>, <name><surname>Huppke</surname><given-names>P</given-names></name>, <name><surname>Schlotawa</surname><given-names>L</given-names></name>, <name><surname>Baethmann</surname><given-names>M</given-names></name>, <name><surname>Carrilho</surname><given-names>I</given-names></name>
<etal>et al</etal>
<article-title>The expanding clinical and genetic spectrum of ATP1A3-related disorders</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>82</volume>: <fpage>945</fpage>&#x2013;<lpage>955</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0000000000000212">10.1212/WNL.0000000000000212</ext-link></comment>
<pub-id pub-id-type="pmid">24523486</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref005">
        <label>5</label>
        <mixed-citation publication-type="journal"><name><surname>Sweney</surname><given-names>MT</given-names></name>, <name><surname>Newcomb</surname><given-names>TM</given-names></name>, <name><surname>Swoboda</surname><given-names>KJ</given-names></name>. <article-title>The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond</article-title>. <source>Pediatr Neurol</source>. <year>2015</year>;<volume>52</volume>: <fpage>56</fpage>&#x2013;<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pediatrneurol.2014.09.015">10.1016/j.pediatrneurol.2014.09.015</ext-link></comment>
<pub-id pub-id-type="pmid">25447930</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref006">
        <label>6</label>
        <mixed-citation publication-type="journal"><name><surname>Viollet</surname><given-names>L</given-names></name>, <name><surname>Glusman</surname><given-names>G</given-names></name>, <name><surname>Murphy</surname><given-names>KJ</given-names></name>, <name><surname>Newcomb</surname><given-names>TM</given-names></name>, <name><surname>Reyna</surname><given-names>SP</given-names></name>, <name><surname>Sweney</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>: <fpage>e0127045</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0127045">10.1371/journal.pone.0127045</ext-link></comment>
<pub-id pub-id-type="pmid">25996915</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref007">
        <label>7</label>
        <mixed-citation publication-type="journal"><name><surname>Panagiotakaki</surname><given-names>E</given-names></name>, <name><surname>De</surname><given-names>GE</given-names></name>, <name><surname>Stagnaro</surname><given-names>M</given-names></name>, <name><surname>Heinzen</surname><given-names>EL</given-names></name>, <name><surname>Fons</surname><given-names>C</given-names></name>, <name><surname>Sisodiya</surname><given-names>S</given-names></name>
<etal>et al</etal>
<article-title>Clinical profile of patients with ATP1A3 mutations in Alternating Hemiplegia of Childhood-a study of 155 patients</article-title>. <source>Orphanet J Rare Dis</source>. <year>2015</year>;<volume>10</volume>: <fpage>123</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13023-015-0335-5">10.1186/s13023-015-0335-5</ext-link></comment>
<pub-id pub-id-type="pmid">26410222</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref008">
        <label>8</label>
        <mixed-citation publication-type="journal"><name><surname>de Carvalho</surname><given-names>Aguiar P</given-names></name>, <name><surname>Sweadner</surname><given-names>KJ</given-names></name>, <name><surname>Penniston</surname><given-names>JT</given-names></name>, <name><surname>Zaremba</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Caton</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>Mutations in the Na,K-ATPase &#x3B1;3 gene <italic>ATP1A3</italic> are associated with rapid-onset dystonia parkinsonism</article-title>. <source>Neuron</source>. <year>2004</year>;<volume>43</volume>: <fpage>169</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="pmid">15260953</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref009">
        <label>9</label>
        <mixed-citation publication-type="journal"><name><surname>Heinzen</surname><given-names>EL</given-names></name>, <name><surname>Swoboda</surname><given-names>KJ</given-names></name>, <name><surname>Gurrieri</surname><given-names>F</given-names></name>, <name><surname>Nicole</surname><given-names>S</given-names></name>, <name><surname>de Vries</surname><given-names>B</given-names></name>, <name><surname>Tiziano</surname><given-names>FD</given-names></name>
<etal>et al</etal>
<article-title><italic>De novo</italic> mutations in <italic>ATP1A3</italic> cause alternating hemiplegia of childhood</article-title>. <source>Nat Genet</source>. <year>2012</year>;<volume>44</volume>: <fpage>1030</fpage>&#x2013;<lpage>1034</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2358">10.1038/ng.2358</ext-link></comment>
<pub-id pub-id-type="pmid">22842232</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref010">
        <label>10</label>
        <mixed-citation publication-type="journal"><name><surname>Paciorkowski</surname><given-names>AR</given-names></name>, <name><surname>McDaniel</surname><given-names>SS</given-names></name>, <name><surname>Jansen</surname><given-names>LA</given-names></name>, <name><surname>Tully</surname><given-names>H</given-names></name>, <name><surname>Tuttle</surname><given-names>E</given-names></name>, <name><surname>Ghoneim</surname><given-names>DH</given-names></name>
<etal>et al</etal>
<article-title>Novel mutations in <italic>ATP1A3</italic> associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly</article-title>. <source>Epilepsia</source>. <year>2015</year>;<volume>56</volume>: <fpage>422</fpage>&#x2013;<lpage>430</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/epi.12914">10.1111/epi.12914</ext-link></comment>
<pub-id pub-id-type="pmid">25656163</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref011">
        <label>11</label>
        <mixed-citation publication-type="journal"><name><surname>Sasaki</surname><given-names>M</given-names></name>, <name><surname>Ishii</surname><given-names>A</given-names></name>, <name><surname>Saito</surname><given-names>Y</given-names></name>, <name><surname>Morisada</surname><given-names>N</given-names></name>, <name><surname>Iijima</surname><given-names>K</given-names></name>, <name><surname>Takada</surname><given-names>S</given-names></name>
<etal>et al</etal>
<article-title>Genotype-phenotype correlations in alternating hemiplegia of childhood</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>82</volume>: <fpage>482</fpage>&#x2013;<lpage>490</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0000000000000102">10.1212/WNL.0000000000000102</ext-link></comment>
<pub-id pub-id-type="pmid">24431296</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref012">
        <label>12</label>
        <mixed-citation publication-type="journal"><name><surname>Demos</surname><given-names>MK</given-names></name>, <name><surname>van Karnebeek</surname><given-names>CDM</given-names></name>, <name><surname>Ross</surname><given-names>CJD</given-names></name>, <name><surname>Adam</surname><given-names>S</given-names></name>, <name><surname>Shen</surname><given-names>Y</given-names></name>, <name><surname>Zhan</surname><given-names>SH</given-names></name>
<etal>et al</etal>
<article-title>A novel recurrent mutation in <italic>ATP1A3</italic> causes CAPOS syndrome</article-title>. <source>Orph J Rare Dis</source>. <year>2014</year>;<volume>9</volume>: <fpage>15</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0151429.ref013">
        <label>13</label>
        <mixed-citation publication-type="journal"><name><surname>Brashear</surname><given-names>A</given-names></name>, <name><surname>Mink</surname><given-names>JW</given-names></name>, <name><surname>Hill</surname><given-names>DF</given-names></name>, <name><surname>Boggs</surname><given-names>N</given-names></name>, <name><surname>McCall</surname><given-names>WV</given-names></name>, <name><surname>Stacy</surname><given-names>MA</given-names></name>
<etal>et al</etal>
<article-title>ATP1A3 mutations in infants: a new rapid-onset dystonia-parkinsonism phenotype characterized by motor delay and ataxia</article-title>. <source>Dev Med Child Neurol</source>. <year>2012</year>;<volume>54</volume>: <fpage>1065</fpage>&#x2013;<lpage>1067</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1469-8749.2012.04421.x">10.1111/j.1469-8749.2012.04421.x</ext-link></comment>
<pub-id pub-id-type="pmid">22924536</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref014">
        <label>14</label>
        <mixed-citation publication-type="journal"><name><surname>Rosewich</surname><given-names>H</given-names></name>, <name><surname>Baethmann</surname><given-names>M</given-names></name>, <name><surname>Ohlenbusch</surname><given-names>A</given-names></name>, <name><surname>Gartner</surname><given-names>J</given-names></name>, <name><surname>Brockmann</surname><given-names>K</given-names></name>. <article-title>A novel ATP1A3 mutation with unique clinical presentation</article-title>. <source>J Neurol Sci</source>. <year>2014</year>;<volume>341</volume>: <fpage>133</fpage>&#x2013;<lpage>135</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jns.2014.03.034">10.1016/j.jns.2014.03.034</ext-link></comment>
<pub-id pub-id-type="pmid">24713507</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref015">
        <label>15</label>
        <mixed-citation publication-type="journal"><name><surname>Dard</surname><given-names>R</given-names></name>, <name><surname>Mignot</surname><given-names>C</given-names></name>, <name><surname>Durr</surname><given-names>A</given-names></name>, <name><surname>Lesca</surname><given-names>G</given-names></name>, <name><surname>Sanlaville</surname><given-names>D</given-names></name>, <name><surname>Roze</surname><given-names>E</given-names></name>
<etal>et al</etal>
<article-title>Relapsing encephalopathy with cerebellar ataxia related to an ATP1A3 mutation</article-title>. <source>Dev Med Child Neurol</source>. <year>2015</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/dmcn.12927">10.1111/dmcn.12927</ext-link></comment></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref016">
        <label>16</label>
        <mixed-citation publication-type="journal"><name><surname>Sasaki</surname><given-names>M</given-names></name>, <name><surname>Ishii</surname><given-names>A</given-names></name>, <name><surname>Saito</surname><given-names>Y</given-names></name>, <name><surname>Hirose</surname><given-names>S</given-names></name>. <article-title>Intermediate form between alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism</article-title>. <source>Mov Disord</source>. <year>2014</year>;<volume>29</volume>: <fpage>153</fpage>&#x2013;<lpage>154</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.25659">10.1002/mds.25659</ext-link></comment>
<pub-id pub-id-type="pmid">24123283</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref017">
        <label>17</label>
        <mixed-citation publication-type="journal"><name><surname>Oblak</surname><given-names>AL</given-names></name>, <name><surname>Hagen</surname><given-names>MC</given-names></name>, <name><surname>Sweadner</surname><given-names>KJ</given-names></name>, <name><surname>Haq</surname><given-names>I</given-names></name>, <name><surname>Whitlow</surname><given-names>CT</given-names></name>, <name><surname>Maldjian</surname><given-names>JA</given-names></name>
<etal>et al</etal>
<article-title>Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the <italic>ATP1A3</italic> gene: a neuropathologic and neuroanatomical study of four siblings</article-title>. <source>Acta Neuropathol</source>. <year>2014</year>;<volume>128</volume>: <fpage>81</fpage>&#x2013;<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00401-014-1279-x">10.1007/s00401-014-1279-x</ext-link></comment>
<pub-id pub-id-type="pmid">24803225</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref018">
        <label>18</label>
        <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>C</given-names></name>, <name><surname>Saunders</surname><given-names>AJ</given-names></name>. <article-title>An emerging role for ubiquilin 1 in regulating protein quality control system and in disease pathogenesis</article-title>. <source>Discov Med</source>. <year>2009</year>;<volume>8</volume>: <fpage>18</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="pmid">19772837</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref019">
        <label>19</label>
        <mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>DR</given-names></name>, <name><surname>Sincan</surname><given-names>M</given-names></name>, <name><surname>Fuentes</surname><given-names>FK</given-names></name>, <name><surname>Mullikin</surname><given-names>JC</given-names></name>, <name><surname>Pierson</surname><given-names>TM</given-names></name>, <name><surname>Toro</surname><given-names>C</given-names></name>
<etal>et al</etal>
<article-title>Analysis of DNA sequence variants detected by high-throughput sequencing</article-title>. <source>Hum Mutat</source>. <year>2012</year>;<volume>33</volume>: <fpage>599</fpage>&#x2013;<lpage>608</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/humu.22035">10.1002/humu.22035</ext-link></comment>
<pub-id pub-id-type="pmid">22290882</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref020">
        <label>20</label>
        <mixed-citation publication-type="journal"><name><surname>Kanai</surname><given-names>R</given-names></name>, <name><surname>Ogawa</surname><given-names>H</given-names></name>, <name><surname>Vilsen</surname><given-names>B</given-names></name>, <name><surname>Cornelius</surname><given-names>F</given-names></name>, <name><surname>Toyoshima</surname><given-names>C</given-names></name>. <article-title>Crystal structure of a Na<sup>+</sup>-bound Na<sup>+</sup>,K<sup>+</sup>-ATPase preceding the E1P state</article-title>. <source>Nature</source>. <year>2013</year>;<volume>502</volume>: <fpage>201</fpage>&#x2013;<lpage>206</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature12578">10.1038/nature12578</ext-link></comment>
<pub-id pub-id-type="pmid">24089211</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref021">
        <label>21</label>
        <mixed-citation publication-type="journal"><name><surname>Shinoda</surname><given-names>T</given-names></name>, <name><surname>Ogawa</surname><given-names>H</given-names></name>, <name><surname>Cornelius</surname><given-names>F</given-names></name>, <name><surname>Toyoshima</surname><given-names>C</given-names></name>. <article-title>Crystal structure of the sodium-potassium pump at 2.4 &#xC5; resolution</article-title>. <source>Nature</source>. <year>2009</year>;<volume>459</volume>: <fpage>446</fpage>&#x2013;<lpage>450</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature07939">10.1038/nature07939</ext-link></comment>
<pub-id pub-id-type="pmid">19458722</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref022">
        <label>22</label>
        <mixed-citation publication-type="journal"><article-title>The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations</article-title>. <source>Mov Disord</source>. <year>2003</year>;<volume>18</volume>: <fpage>738</fpage>&#x2013;<lpage>750</lpage>. <pub-id pub-id-type="pmid">12815652</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref023">
        <label>23</label>
        <mixed-citation publication-type="journal"><name><surname>Krystkowiak</surname><given-names>P</given-names></name>, <name><surname>du Montcel</surname><given-names>ST</given-names></name>, <name><surname>Vercueil</surname><given-names>L</given-names></name>, <name><surname>Houeto</surname><given-names>JL</given-names></name>, <name><surname>Lagrange</surname><given-names>C</given-names></name>, <name><surname>Cornu</surname><given-names>P</given-names></name>
<etal>et al</etal>
<article-title>Reliability of the Burke-Fahn-Marsden scale in a multicenter trial for dystonia</article-title>. <source>Mov Disord</source>. <year>2007</year>;<volume>22</volume>: <fpage>685</fpage>&#x2013;<lpage>689</lpage>. <pub-id pub-id-type="pmid">17274034</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref024">
        <label>24</label>
        <mixed-citation publication-type="journal"><name><surname>McCall</surname><given-names>WV</given-names></name>, <name><surname>Dunn</surname><given-names>AG</given-names></name>, <name><surname>Rosenquist</surname><given-names>P</given-names></name>, <name><surname>Hughes</surname><given-names>D</given-names></name>. <article-title>Proxy validation of patient self-reports of ADL and IADL function before and after electroconvulsive therapy</article-title>. <source>J ECT</source>. <year>2002</year>;<volume>18</volume>: <fpage>74</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="pmid">12195134</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref025">
        <label>25</label>
        <mixed-citation publication-type="journal"><name><surname>Brashear</surname><given-names>A</given-names></name>, <name><surname>Cook</surname><given-names>JF</given-names></name>, <name><surname>Hill</surname><given-names>DF</given-names></name>, <name><surname>Amponsah</surname><given-names>A</given-names></name>, <name><surname>Snively</surname><given-names>B</given-names></name>, <name><surname>Light</surname><given-names>LS</given-names></name>
<etal>et al</etal>
<article-title>Psychiatric disorders in rapid-onset dystonia parkinsonism</article-title>. <source>Neurology</source>. <year>2012</year>;<volume>79</volume>: <fpage>1168</fpage>&#x2013;<lpage>1173</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0b013e3182698d6c">10.1212/WNL.0b013e3182698d6c</ext-link></comment>
<pub-id pub-id-type="pmid">22933743</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref026">
        <label>26</label>
        <mixed-citation publication-type="journal"><name><surname>Cook</surname><given-names>JF</given-names></name>, <name><surname>Hill</surname><given-names>DF</given-names></name>, <name><surname>Snively</surname><given-names>BM</given-names></name>, <name><surname>Boggs</surname><given-names>N</given-names></name>, <name><surname>Suerken</surname><given-names>CK</given-names></name>, <name><surname>Haq</surname><given-names>I</given-names></name>
<etal>et al</etal>
<article-title>Cognitive impairment in rapid-onset dystonia-parkinsonism</article-title>. <source>Mov Disord</source>. <year>2014</year>;<volume>29</volume>: <fpage>344</fpage>&#x2013;<lpage>350</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.25790">10.1002/mds.25790</ext-link></comment>
<pub-id pub-id-type="pmid">24436111</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref027">
        <label>27</label>
        <mixed-citation publication-type="journal"><name><surname>Nakagawa</surname><given-names>O</given-names></name>, <name><surname>Arnold</surname><given-names>M</given-names></name>, <name><surname>Nakagawa</surname><given-names>M</given-names></name>, <name><surname>Hamada</surname><given-names>H</given-names></name>, <name><surname>Shelton</surname><given-names>JM</given-names></name>, <name><surname>Kusano</surname><given-names>H</given-names></name>
<etal>et al</etal>
<article-title>Centronuclear myopathy in mice lacking a novel muscle-specific protein kinase transcriptionally regulated by MEF2</article-title>. <source>Genes Dev</source>. <year>2005</year>;<volume>19</volume>: <fpage>2066</fpage>&#x2013;<lpage>2077</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.1338705">10.1101/gad.1338705</ext-link></comment>
<pub-id pub-id-type="pmid">16140986</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref028">
        <label>28</label>
        <mixed-citation publication-type="journal"><name><surname>Heinzen</surname><given-names>EL</given-names></name>, <name><surname>Arzimanoglou</surname><given-names>A</given-names></name>, <name><surname>Brashear</surname><given-names>A</given-names></name>, <name><surname>Clapcote</surname><given-names>SJ</given-names></name>, <name><surname>Gurrieri</surname><given-names>F</given-names></name>, <name><surname>Goldstein</surname><given-names>DB</given-names></name>
<etal>et al</etal>
<article-title>Distinct neurological disorders with <italic>ATP1A3</italic> mutations</article-title>. <source>Lancet Neurol</source>. <year>2014</year>;<volume>13</volume>: <fpage>503</fpage>&#x2013;<lpage>514</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(14)70011-0">10.1016/S1474-4422(14)70011-0</ext-link></comment>
<pub-id pub-id-type="pmid">24739246</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref029">
        <label>29</label>
        <mixed-citation publication-type="journal"><name><surname>Viollet</surname><given-names>L</given-names></name>, <name><surname>Glusman</surname><given-names>G</given-names></name>, <name><surname>Murphy</surname><given-names>KJ</given-names></name>, <name><surname>Newcomb</surname><given-names>TM</given-names></name>, <name><surname>Reyna</surname><given-names>SP</given-names></name>, <name><surname>Sweney</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>: <fpage>e0127045</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0127045">10.1371/journal.pone.0127045</ext-link></comment>
<pub-id pub-id-type="pmid">25996915</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref030">
        <label>30</label>
        <mixed-citation publication-type="journal"><name><surname>Nicolaides</surname><given-names>P</given-names></name>, <name><surname>Appleton</surname><given-names>RE</given-names></name>, <name><surname>Fryer</surname><given-names>A</given-names></name>. <article-title>Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS): a new syndrome</article-title>. <source>J Med Genet</source>. <year>1996</year>;<volume>33</volume>: <fpage>419</fpage>&#x2013;<lpage>421</lpage>. <pub-id pub-id-type="pmid">8733056</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref031">
        <label>31</label>
        <mixed-citation publication-type="journal"><name><surname>Rosewich</surname><given-names>H</given-names></name>, <name><surname>Weise</surname><given-names>D</given-names></name>, <name><surname>Ohlenbusch</surname><given-names>A</given-names></name>, <name><surname>Gartner</surname><given-names>J</given-names></name>, <name><surname>Brockmann</surname><given-names>K</given-names></name>. <article-title>Phenotypic overlap of alternating hemiplegia of childhood and CAPOS syndrome</article-title>. <source>Neurology</source>. <year>2014</year>;<volume>83</volume>: <fpage>861</fpage>&#x2013;<lpage>863</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0000000000000735">10.1212/WNL.0000000000000735</ext-link></comment>
<pub-id pub-id-type="pmid">25056583</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref032">
        <label>32</label>
        <mixed-citation publication-type="journal"><name><surname>Panagiotakaki</surname><given-names>E</given-names></name>, <name><surname>Gobbi</surname><given-names>G</given-names></name>, <name><surname>Neville</surname><given-names>B</given-names></name>, <name><surname>Ebinger</surname><given-names>F</given-names></name>, <name><surname>Campistol</surname><given-names>J</given-names></name>, <name><surname>Nevsimalova</surname><given-names>S</given-names></name>
<etal>et al</etal>
<article-title>Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults</article-title>. <source>Brain</source>. <year>2010</year>;<volume>133</volume>: <fpage>3598</fpage>&#x2013;<lpage>3610</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/brain/awq295">10.1093/brain/awq295</ext-link></comment>
<pub-id pub-id-type="pmid">20974617</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref033">
        <label>33</label>
        <mixed-citation publication-type="journal"><name><surname>Kaneko</surname><given-names>M</given-names></name>, <name><surname>Desai</surname><given-names>BS</given-names></name>, <name><surname>Cook</surname><given-names>B</given-names></name>. <article-title>Ionic leakage underlies a gain-of-function effect of dominant disease mutations affecting diverse P-type ATPases</article-title>. <source>Nat Genet</source>. <year>2014</year>;<volume>46</volume>: <fpage>144</fpage>&#x2013;<lpage>151</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2850">10.1038/ng.2850</ext-link></comment>
<pub-id pub-id-type="pmid">24336169</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref034">
        <label>34</label>
        <mixed-citation publication-type="journal"><name><surname>Azizan</surname><given-names>EA</given-names></name>, <name><surname>Poulsen</surname><given-names>H</given-names></name>, <name><surname>Tuluc</surname><given-names>P</given-names></name>, <name><surname>Zhou</surname><given-names>J</given-names></name>, <name><surname>Clausen</surname><given-names>MV</given-names></name>, <name><surname>Lieb</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>: <fpage>1055</fpage>&#x2013;<lpage>1060</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2716">10.1038/ng.2716</ext-link></comment>
<pub-id pub-id-type="pmid">23913004</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref035">
        <label>35</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Jazayeri</surname><given-names>D</given-names></name>, <name><surname>Corry</surname><given-names>B</given-names></name>, <name><surname>McSweeney</surname><given-names>KM</given-names></name>, <name><surname>Heinzen</surname><given-names>EL</given-names></name>, <name><surname>Goldstein</surname><given-names>DB</given-names></name>
<etal>et al</etal>
<article-title>A functional correlate of severity in alternating hemiplegia of childhood</article-title>. <source>Neurobiol Dis</source>. <year>2015</year>;<volume>77</volume>: <fpage>88</fpage>&#x2013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2015.02.002">10.1016/j.nbd.2015.02.002</ext-link></comment>
<pub-id pub-id-type="pmid">25681536</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref036">
        <label>36</label>
        <mixed-citation publication-type="journal"><name><surname>Ryno</surname><given-names>LM</given-names></name>, <name><surname>Wiseman</surname><given-names>RL</given-names></name>, <name><surname>Kelly</surname><given-names>JW</given-names></name>. <article-title>Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases</article-title>. <source>Curr Opin Chem Biol</source>. <year>2013</year>;<volume>17</volume>: <fpage>346</fpage>&#x2013;<lpage>352</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cbpa.2013.04.009">10.1016/j.cbpa.2013.04.009</ext-link></comment>
<pub-id pub-id-type="pmid">23647985</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref037">
        <label>37</label>
        <mixed-citation publication-type="journal"><name><surname>Nijholt</surname><given-names>DA</given-names></name>, <name><surname>De</surname><given-names>KL</given-names></name>, <name><surname>Elfrink</surname><given-names>HL</given-names></name>, <name><surname>Hoozemans</surname><given-names>JJ</given-names></name>, <name><surname>Scheper</surname><given-names>W</given-names></name>. <article-title>Removing protein aggregates: the role of proteolysis in neurodegeneration</article-title>. <source>Curr Med Chem</source>. <year>2011</year>;<volume>18</volume>: <fpage>2459</fpage>&#x2013;<lpage>2476</lpage>. <pub-id pub-id-type="pmid">21568912</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref038">
        <label>38</label>
        <mixed-citation publication-type="journal"><name><surname>Marin</surname><given-names>I</given-names></name>. <article-title>The ubiquilin gene family: evolutionary patterns and functional insights</article-title>. <source>BMC Evol Biol</source>. <year>2014</year>;<volume>14</volume>: <fpage>63</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2148-14-63">10.1186/1471-2148-14-63</ext-link></comment>
<pub-id pub-id-type="pmid">24674348</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref039">
        <label>39</label>
        <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>DY</given-names></name>, <name><surname>Arnott</surname><given-names>D</given-names></name>, <name><surname>Brown</surname><given-names>EJ</given-names></name>. <article-title>Ubiquilin4 is an adaptor protein that recruits ubiquilin1 to the autophagy machinery</article-title>. <source>EMBO Rep</source>. <year>2013</year>;<volume>14</volume>: <fpage>373</fpage>&#x2013;<lpage>381</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/embor.2013.22">10.1038/embor.2013.22</ext-link></comment>
<pub-id pub-id-type="pmid">23459205</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref040">
        <label>40</label>
        <mixed-citation publication-type="journal"><name><surname>Robberecht</surname><given-names>W</given-names></name>, <name><surname>Philips</surname><given-names>T</given-names></name>. <article-title>The changing scene of amyotrophic lateral sclerosis</article-title>. <source>Nat Rev Neurosci</source>. <year>2013</year>;<volume>14</volume>: <fpage>248</fpage>&#x2013;<lpage>264</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrn3430">10.1038/nrn3430</ext-link></comment>
<pub-id pub-id-type="pmid">23463272</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref041">
        <label>41</label>
        <mixed-citation publication-type="journal"><name><surname>Ugwu</surname><given-names>F</given-names></name>, <name><surname>Rollinson</surname><given-names>S</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Gerhard</surname><given-names>A</given-names></name>, <name><surname>Richardson</surname><given-names>A</given-names></name>, <name><surname>Jones</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>A <italic>UBQLN2</italic> variant of unknown significance in frontotemporal lobar degeneration</article-title>. <source>Neurobiol Aging</source>. <year>2015</year>;<volume>36</volume>: <fpage>546</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neurobiolaging.2014.08.002">10.1016/j.neurobiolaging.2014.08.002</ext-link></comment><pub-id pub-id-type="pmid">25179229</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref042">
        <label>42</label>
        <mixed-citation publication-type="journal"><name><surname>Lein</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Genome-wide atlas of gene expression in the adult mouse brain</article-title>. <source>Nature</source>. <year>2007</year>;<volume>445</volume>: <fpage>168</fpage>&#x2013;<lpage>176</lpage>. <pub-id pub-id-type="pmid">17151600</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref043">
        <label>43</label>
        <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>LT</given-names></name>, <name><surname>Gilman</surname><given-names>AG</given-names></name>, <name><surname>Kozasa</surname><given-names>T</given-names></name>. <article-title>A candidate target for G protein action in brain</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>: <fpage>26931</fpage>&#x2013;<lpage>26938</lpage>. <pub-id pub-id-type="pmid">10480904</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref044">
        <label>44</label>
        <mixed-citation publication-type="journal"><name><surname>Ge</surname><given-names>X</given-names></name>, <name><surname>Qiu</surname><given-names>Y</given-names></name>, <name><surname>Loh</surname><given-names>HH</given-names></name>, <name><surname>Law</surname><given-names>PY</given-names></name>. <article-title>GRIN1 regulates micro-opioid receptor activities by tethering the receptor and G protein in the lipid raft</article-title>. <source>J Biol Chem</source>. <year>2009</year>;<volume>284</volume>: <fpage>36521</fpage>&#x2013;<lpage>36534</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M109.024109">10.1074/jbc.M109.024109</ext-link></comment>
<pub-id pub-id-type="pmid">19861419</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref045">
        <label>45</label>
        <mixed-citation publication-type="journal"><name><surname>Nordman</surname><given-names>JC</given-names></name>, <name><surname>Kabbani</surname><given-names>N</given-names></name>. <article-title>An interaction between alpha7 nicotinic receptors and a G-protein pathway complex regulates neurite growth in neural cells</article-title>. <source>J Cell Sci</source>. <year>2012</year>;<volume>125</volume>: <fpage>5502</fpage>&#x2013;<lpage>5513</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/jcs.110379">10.1242/jcs.110379</ext-link></comment>
<pub-id pub-id-type="pmid">22956546</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref046">
        <label>46</label>
        <mixed-citation publication-type="journal"><name><surname>Prudente</surname><given-names>CN</given-names></name>, <name><surname>Hess</surname><given-names>EJ</given-names></name>, <name><surname>Jinnah</surname><given-names>HA</given-names></name>. <article-title>Dystonia as a network disorder: what is the role of the cerebellum?</article-title>
<source>Neuroscience</source>. <year>2014</year>;<volume>260</volume>: <fpage>23</fpage>&#x2013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.neuroscience.2013.11.062">10.1016/j.neuroscience.2013.11.062</ext-link></comment>
<pub-id pub-id-type="pmid">24333801</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref047">
        <label>47</label>
        <mixed-citation publication-type="journal"><name><surname>Argyelan</surname><given-names>M</given-names></name>, <name><surname>Carbon</surname><given-names>M</given-names></name>, <name><surname>Niethammer</surname><given-names>M</given-names></name>, <name><surname>Ulug</surname><given-names>AM</given-names></name>, <name><surname>Voss</surname><given-names>HU</given-names></name>, <name><surname>Bressman</surname><given-names>SB</given-names></name>
<etal>et al</etal>
<article-title>Cerebellothalamocortical connectivity regulates penetrance in dystonia</article-title>. <source>J Neurosci</source>. <year>2009</year>;<volume>29</volume>: <fpage>9740</fpage>&#x2013;<lpage>9747</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1523/JNEUROSCI.2300-09">10.1523/JNEUROSCI.2300-09</ext-link></comment>
<pub-id pub-id-type="pmid">19657027</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref048">
        <label>48</label>
        <mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>VB</given-names></name>, <name><surname>Jinnah</surname><given-names>HA</given-names></name>, <name><surname>Hess</surname><given-names>EJ</given-names></name>. <article-title>Convergent mechanisms in etiologically-diverse dystonias</article-title>. <source>Expert Opin Ther Targets</source>. <year>2011</year>;<volume>15</volume>: <fpage>1387</fpage>&#x2013;<lpage>1403</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1517/14728222.2011.641533">10.1517/14728222.2011.641533</ext-link></comment>
<pub-id pub-id-type="pmid">22136648</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref049">
        <label>49</label>
        <mixed-citation publication-type="journal"><name><surname>Sadnicka</surname><given-names>A</given-names></name>, <name><surname>Hoffland</surname><given-names>BS</given-names></name>, <name><surname>Bhatia</surname><given-names>KP</given-names></name>, <name><surname>van de Warrenburg</surname><given-names>BP</given-names></name>, <name><surname>Edwards</surname><given-names>MJ</given-names></name>. <article-title>The cerebellum in dystonia&#x2014;help or hindrance?</article-title>
<source>Clin Neurophysiol</source>. <year>2012</year>;<volume>123</volume>: <fpage>65</fpage>&#x2013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clinph.2011.04.027">10.1016/j.clinph.2011.04.027</ext-link></comment>
<pub-id pub-id-type="pmid">22078259</pub-id></mixed-citation>
      </ref>
      <ref id="pone.0151429.ref050">
        <label>50</label>
        <mixed-citation publication-type="journal"><name><surname>Fremont</surname><given-names>R</given-names></name>, <name><surname>Calderon</surname><given-names>DP</given-names></name>, <name><surname>Maleki</surname><given-names>S</given-names></name>, <name><surname>Khodakhah</surname><given-names>K</given-names></name>. <article-title>Abnormal high-frequency burst firing of cerebellar neurons in rapid-onset dystonia-parkinsonism</article-title>. <source>J Neurosci</source>. <year>2014</year>;<volume>34</volume>: <fpage>11723</fpage>&#x2013;<lpage>11732</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1523/JNEUROSCI.1409-14.2014">10.1523/JNEUROSCI.1409-14.2014</ext-link></comment>
<pub-id pub-id-type="pmid">25164667</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
